Modulation of alpha-synuclein aggregation by dopamine analogs

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Latawiec, Diane ^a,b   Herrera, Fernando ^a,b   Bek, Alpan ^c   Losasso, Valeria ^a   Candotti, Michela ^a,b   Benetti, Federico ^a,b   Carlino, Elvio ^d   Kranjc, Agata ^a,b   Lazzarino, Marco ^c,d   Gustincich, Stefano ^a,b   Carloni, Paolo ^a,b   Legname, Giuseppe ^a,b,e  

^a SISSA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c Consorzio Per il Centro di Biomedicina Molecolare Center for Molecular Biomedicine ^*  (Italy)

^d LABORATORIO TASC   (Italy)

^e SINCROTRONE TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 TERT BUTYLPHENOL; 4 (2 AMINOETHYL)ANILINE; 5 HYDROXYINDOLE; 6 AMINOINDOLE; ALPHA SYNUCLEIN; DOPAMINE DERIVATIVE; LIGAND; TYRAMINE; UNCLASSIFIED DRUG; 5-HYDROXYINDOLE; DOPAMINE; DRUG DERIVATIVE; INDOLE DERIVATIVE; RECOMBINANT PROTEIN; WATER;

ARTICLE; ASSAY; ATOMIC FORCE MICROSCOPY; COMPUTER MODEL; COVALENT BOND; ELECTRICITY; EXPERIMENTATION; HUMAN; MOLECULAR DYNAMICS; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN STRUCTURE; SCREENING; TRANSMISSION ELECTRON MICROSCOPY; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; GENETICS; HYDROGEN BOND; HYDROPHOBICITY; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN CONFORMATION; STATIC ELECTRICITY; ULTRASTRUCTURE;

ALPHA-SYNUCLEIN; CIRCULAR DICHROISM; DOPAMINE; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; INDOLES; LIGANDS; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; STATIC ELECTRICITY; TYRAMINE; WATER;

EID: 77949522461     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009234     Document Type: Article

References (47)

1. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
2. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, et al. (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 10-15.
3. Lewy FH (1912) Handbuch der Neurologie. Berlin: Springer.
4. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301.
5. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272.
6. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884.
7. Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, et al. (2000) Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci 920: 42-45.
8. Goedert M (2001) Parkinson's disease and other alpha-synucleinopathies. Clin Chem Lab Med 39: 308-312.
9. Dawson TM, Dawson VL (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111: 145-151.
10. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
11. Jenco JM, Rawlingson A, Daniels B, Morris AJ (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37: 4901-4909.
12. Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J 15: 916-926.
13. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, et al. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21: 8053-8061.
14. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, et al. (2001) alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 98: 9110-9115.
15. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3: 932-942.
16. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099.
17. Xu J, Kao SY, Lee FJ, Song W, Jin LW, et al. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8: 600-606.
18. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K (2003) The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 4: 727-738.
19. Fountaine TM, Wade-Martins R (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 85: 351-363.
20. Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, et al. (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115: 193-203.
21. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346-1349.
22. Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. Faseb J 19: 1377-1379.
23. Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, et al. (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26: 10068-10078.
24. Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H (2007) Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem 282: 31621-31630.
25. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, et al. (2005) Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. Febs J 272: 3661-3672.
26. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, et al. (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochromemediated conformational alterations. J Biol Chem 280: 21212-21219.
27. Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282: 15597-15605.
28. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc 127: 476-477.
29. Herrera FE, Chesi A, Paleologou KE, Schmid A, Munoz A, et al. (2008) Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE 3: e3394.
30. Bostrom J, Hogner A, Schmitt S (2006) Do structurally similar ligands bind in a similar fashion? J Med Chem 49: 6716-6725.
31. von Grotthuss M, Koczyk G, Pas J, Wyrwicz LS, Rychlewski L (2004) Ligand.Info small-molecule Meta-Database. Comb Chem High Throughput Screen 7: 757-761.
32. Tanimoto T (1957) IBM Internal Report.
33. Slutzki M, Jaitin DA, Yehezkel TB, Schreiber G (2006) Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity. J Mol Biol 360: 1019-1030.
34. Huang C, Ren G, Zhou H, Wang CC (2005) A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif 42: 173-177.
35. Conway KA, Harper JD, Lansbury PT Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39: 2552-2563.
36. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274: 9843-9846.
37. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, et al. (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274: 19509-19512.
38. Jarrett JT, Lansbury PT Jr (1992) Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry 31: 12345-12352.
39. Kaylor J, Bodner N, Edridge S, Yamin G, Hong DP, et al. (2005) Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J Mol Biol 353: 357-372.
40. van Raaij ME, van Gestel J, Segers-Nolten IM, de Leeuw SW, Subramaniam V (2008) Concentration dependence of alpha-synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory. Biophys J 95: 4871-4878.
41. van Raaij ME, Segers-Nolten IM, Subramaniam V (2006) Quantitative morphological analysis reveals ultrastructural diversity of amyloid fibrils from alpha-synuclein mutants. Biophys J 91: L96-98.
42. Wright JA, Brown DR (2008) Alpha-synuclein and its role in metal binding: relevance to Parkinson's disease. J Neurosci Res 86: 496-503.
43. Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276: 44284-44296.
44. Tashiro M, Kojima M, Kihara H, Kasai K, Kamiyoshihara T, et al. (2008) Characterization of fibrillation process of alpha-synuclein at the initial stage. Biochem Biophys Res Commun 369: 910-914.
45. Frisch MJ (2001) Gaussian98. revision A.1x ed. Pittsburgh: Gaussian Inc.
46. Muchmore SW, Souers AJ, Akritopoulou-Zanze I (2006) The use of threedimensional shape and electrostatic similarity searching in the identification of a melanin-concentrating hormone receptor 1 antagonist. Chem Biol Drug Des 67: 174-176.
47. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.